title: Structural and molecular regulation of lung maturation by intratracheal vascular endothelial growth factor administration in the normally grown and placentally restricted fetus.
abstract: Inhibition of hypoxia signalling leads to respiratory distress syndrome (RDS), whereas administration of vascular endothelial growth factor (VEGF), the most widely characterized hypoxia responsive factor, protects from RDS. In the lung of the chronically hypoxaemic placentally restricted (PR) fetus, there is altered regulation of hypoxia signalling. This leads to reduced surfactant maturation in late gestation and provides evidence for the increased risk of RDS in growth restricted neonates at birth. We evaluated the effect of recombinant human VEGF administration with respect to bypassing the endogenous regulation of hypoxia signalling in the lung of the normally grown and PR sheep fetus. There was no effect of VEGF administration on fetal blood pressure or fetal breathing movements. We examined the effect on the expression of genes regulating VEGF signalling (FLT1 and KDR), angiogenesis (ANGPT1, AQP1, ADM), alveolarization (MMP2, MMP9, TIMP1, COL1A1, ELN), proliferation (IGF1, IGF2, IGF1R, MKI67, PCNA), inflammation (CCL2, CCL4, IL1B, TNFA, TGFB1, IL10) and surfactant maturation (SFTP-A, SFTP-B, SFTP-C, SFTP-D, PCYT1A, LPCAT, LAMP3, ABCA3). Despite the effects of PR on the expression of genes regulating airway remodelling, inflammatory signalling and surfactant maturation, there were very few effects of VEGF administration on gene expression in the lung of both the normally grown and PR fetus. There were, however, positive effects of VEGF administration on percentage tissue, air space and numerical density of SFTP-B positive alveolar epithelial cells in fetal lung tissue. These results provide evidence for the stimulatory effects of VEGF administration on structural maturation in the lung of both the normally grown and PR fetus.
authors.affiliation: Early Origins of Adult Health Research Group.|Molecular & Evolutionary Physiology of the Lung Laboratory, School of Pharmacy & Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia.
authors.forename: Erin V
authors.initials: EV
authors.lastname: McGillick
authors.affiliation: Molecular & Evolutionary Physiology of the Lung Laboratory, School of Pharmacy & Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia.
authors.forename: Sandra
authors.initials: S
authors.lastname: Orgeig
authors.affiliation: Early Origins of Adult Health Research Group.
authors.forename: Janna L
authors.initials: JL
authors.lastname: Morrison
mesh_terms: D000818:Animals; D005260:Female; D005311:Fetal Hypoxia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005325:Fetal Organ Maturity; D008168:Lung / Q000187:drug effects* / Q000196:embryology / Q000378:metabolism; D018919:Neovascularization, Physiologic; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control; D012756:Sheep; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D042461:Vascular Endothelial Growth Factor A